Large-scale study of blood markers in equine atypical myopathy reveals subclinical poisoning and advances in diagnostic and prognostic criteria,Environmental Toxicology and Pharmacology

当前位置： X-MOL 学术 › Environ. Toxicol. Pharmacol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Large-scale study of blood markers in equine atypical myopathy reveals subclinical poisoning and advances in diagnostic and prognostic criteria
Environmental Toxicology and Pharmacology ( IF 4.2 ) Pub Date : 2024-07-18 , DOI: 10.1016/j.etap.2024.104515
Benoît Renaud ₁ , Caroline-J Kruse ₂ , Anne-Christine François ₁ , Carla Cesarini ₃ , Gunther van Loon ₄ , Katrien Palmers ₅ , François Boemer ₆ , Géraldine Luis ₆ , Pascal Gustin ₁ , Dominique-Marie Votion ₁

Affiliation

Equine atypical myopathy (AM) is a severe rhabdomyolysis syndrome primarily caused by hypoglycin A (HGA) and methylenecyclopropylglycine protoxins. This study aimed to refine diagnostic and prognostic criteria for AM while exploring apparently healthy cograzers. Blood samples from 263 horses, including AM cases (n= 95), cograzers (n= 73), colic horses (n= 19), and controls (n= 76), were analyzed for HGA, its toxic metabolite, and acylcarnitines profile. Diseased horses exhibited alterations in acylcarnitines that strongly distinguished them from controls and colic horses. Regression analyses identified distinct acylcarnitines profiles among groups, with cograzers showing intermediate alterations. Age and gelding status emerged as protective factors against AM. Furthermore, serum acylcarnitines profiling was valuable in predicting AM survival, with isovaleryl-/2-methylbutyrylcarnitine (., C5 acylcarnitine) showing promise as both a diagnostic and prognostic marker. Subclinical alterations in cograzers underscore a novel aspect: the presence of subclinical cases of AM.

更新日期：2024-07-18

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南